NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

Authors :: Galipeau, Patricia C.
Li, Xiaohong
Blount, Patricia L.
Maley, Carlo C.
Sanchez, Carissa A.
Odze, Robert D.
Ayub, Kamran
Rabinovitch, Peter S.
Vaughan, Thomas L.
Reid, Brian J.
Source :: PLoS Medicine. Feb, 2007, Vol. 4 Issue 2, p342, 13 p.
Publication Year :: 2007
Abstract: ABSTRACT Background Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett's esophagus (BE), conditions for which [...]

Subjects :: Esophageal diseases -- Research
Adenocarcinoma -- Research
Nonsteroidal anti-inflammatory drugs -- Research

Tools